AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

NUFORMIX PLC

Director's Dealing Jan 10, 2022

4941_dirs_2022-01-10_72f1b35e-bf21-4df3-bbbd-c08588e91898.html

Director's Dealing

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 9789X

Nuformix PLC

10 January 2022

10 January 2022

Nuformix plc

("Nuformix" or the "the Company")

Director/PDMR Shareholding

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that today the Company received notice that Dr Alastair Riddell purchased 400,000 ordinary shares of 0.1 pence each ("Ordinary Shares") at a price of 1.175 pence per share on 10 January 2022.

- Ends -

Nuformix plc via Walbrook
Dr Alastair Riddell, Executive Chairman
Allenby Capital Limited +44 (0) 20 3328 5656
Nick Athanas / George Payne (Corporate Finance)
Stefano Aquilino / Matt Butlin (Sales and Corporate Broking)
Walbrook PR [email protected] or +44 (0)20 7933 8780
Anna Dunphy / Phillip Marriage Tel: +44 (0)7876 741 001 / +44 (0)7867 984 082

Enquiries:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Dr Alastair Riddell

2

Reason for the notification

a)

Position/status

PDMR - Executive Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Nuformix plc

b)

LEI

2138003XG3H3I2J3BJ24

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of nominal value 0.1 pence each

GB00BYW79Y38

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Price(s) Volume(s)
1.175p 400,000

d)

Aggregated information

- Aggregated volume

- Price

- Total

400,000

1.175p

£4,700.00

e)

Date of the transaction

10 January 2022

f)

Place of the transaction

London Stock Exchange, Main Market

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGPUUPGUPPGQU

Talk to a Data Expert

Have a question? We'll get back to you promptly.